– USA, CA / NETHERLANDS, Amsterdam – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer. He succeeds Jan Egberts, M.D., who took on the position of CEO last October on an interim basis.
“We are very pleased to have Mark as CEO of Agendia,” said Pieter van der Meer, a member of Agendia’s Supervisory Board. “His experience in molecular diagnostics, extensive background in laboratory operations, and his success in building new markets make him the ideal person to take Agendia forward.”
“On behalf of Agendia’s board and all its employees, I would like extend our gratitude to Jan Egberts for his leadership over the past year,” said Harry Bartelink, M.D., Ph.D., a member of Agendia’s Supervisory Board. “His work has further developed Agendia into an internationally recognized innovator in molecular diagnostics.”
Straley brings more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services. Most recently he served as President, Anatomical Pathology of Thermo Fisher Scientific (Waltham, Mass.). Prior to this position he was President and CEO of Metamark Genetics (Cambridge, Mass.), a biotech company focusing on the development of prognostic and predictive diagnostic tests for personalized treatment of cancer patients.
From 2005 until 2010 Straley held positions at Johnson & Johnson company Ortho Clinical Diagnostics, first as Worldwide Vice President of Marketing and then as Worldwide President.
“I’m pleased to be able to serve Agendia’s growing number of physician customers and their patients,” Straley said. “I’m firmly committed to laying the foundation for the next level of success, as we expand the sales of MammaPrint®, BluePrint® and our other molecular tests, and as we continue to bring the benefits of our tests to patients around the world.”
Agendia is a privately owned, leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.